Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Madrigal Pharmaceuticals, Inc.’s reported figures.
Plus components not separately reported this period.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s EBIT?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported EBIT of -$56.31M in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s EBIT changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s EBIT decreased by 19.3% year-over-year, from -$47.2M to -$56.31M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s EBIT has grown at a 5.5% compound annual growth rate (CAGR), from -$242.48M to -$300.1M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude